Eli Lilly Gets $1,450 Target as Bernstein Sees Mounjaro Upside

What happened

Bernstein SocGen Group raised its Eli Lilly price target from $1,385 to $1,450 and kept an Outperform rating, expecting modest third-quarter revenue upside led by international Mounjaro sales. Lilly shares were up 0.41% intraday as of 11:50 a.m. ET.

Confirmed

Global impact / market context

A higher price target signals Bernstein expects Lilly's drug sales, especially Mounjaro outside the U.S., to beat modest expectations. That can support investor confidence in future revenue, though a one-time research charge trims 2026 profit even as revenue forecasts rise.

Analyst inference

Bernstein forecasts third-quarter revenue of $22.62 billion, slightly above the $22.45 billion consensus, which means analysts collectively expect less. It also raised 2027 estimates on stronger Zepbound and U.S. Mounjaro sales, while delaying the modeled BALANCE pricing impact to 2028.

Analyst inference

What to watch

1. Bernstein forecasts third-quarter revenue of $22.62 billion, 0.8% above the Bloomberg median consensus of $22.45 billion, and adjusted EPS of $5.48, in line with consensus. Confirmed
2. Bernstein raised its 2027 estimates to revenue of $111.4 billion and EPS of $53.09, mainly on higher Zepbound and U.S. Mounjaro forecasts, which investors can compare with actual results. Proposed
3. Bernstein pushed the modeled BALANCE pricing impact from 2027 to 2028, which supports near-term estimates but is not a permanent improvement in economics, so future pricing pressure remains a risk. Analyst inference

Evidence

• gurufocus.com